Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 84.52 -6.85% -6.22
ALNY closed down 6.85 percent on Friday, March 22, 2019, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical ALNY trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 21 200 DMA Support Bullish -6.85%
Mar 21 Multiple of Ten Bullish Other -6.85%
Mar 20 200 DMA Support Bullish -4.69%
Mar 20 Doji - Bullish? Reversal -4.69%
Mar 19 200 DMA Support Bullish -4.64%
Mar 19 NR7 Range Contraction -4.64%

Older signals for ALNY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Alpha Isis Hemophilia Huntington's Disease Spinal Muscular Atrophy Treatment Of Hemophilia Alnylam Pharmaceuticals Biogen Therapeutic Gene Modulation Deficiency Hemoglobinopathies Hypercholesterolemia Acute Intermittent Porphyria Treatment Of Huntington's Disease
Is ALNY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 141.66
52 Week Low 60.27
Average Volume 813,013
200-Day Moving Average 88.4083
50-Day Moving Average 83.7418
20-Day Moving Average 86.6835
10-Day Moving Average 89.016
Average True Range 3.7753
ADX 12.46
+DI 23.3204
-DI 23.6182
Chandelier Exit (Long, 3 ATRs ) 81.4041
Chandelier Exit (Short, 3 ATRs ) 86.5759
Upper Bollinger Band 92.7654
Lower Bollinger Band 80.6016
Percent B (%b) 0.32
BandWidth 14.032428
MACD Line 1.7673
MACD Signal Line 1.9429
MACD Histogram -0.1756
Fundamentals Value
Market Cap 7.75 Billion
Num Shares 91.7 Million
EPS -5.12
Price-to-Earnings (P/E) Ratio -16.51
Price-to-Sales 159.14
Price-to-Book 9.35
PEG Ratio -0.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 93.76
Resistance 3 (R3) 94.71 92.58 92.22
Resistance 2 (R2) 92.58 90.23 92.11 91.71
Resistance 1 (R1) 88.55 88.77 87.49 87.60 91.19
Pivot Point 86.42 86.42 85.89 85.95 86.42
Support 1 (S1) 82.39 84.07 81.33 81.44 77.85
Support 2 (S2) 80.26 82.61 79.79 77.33
Support 3 (S3) 76.23 80.26 76.82
Support 4 (S4) 75.28